Abstract: Objective To evaluate the clinical effi cacy of Docetaxel-based and Oxaliplatin-based chemotherapy in the fi rst-line treatment of advanced gastric cancer（AGC）in different Lauren types. Methods Retrospective analysis of 311 AGC cases in PLA hospital was involved. Among them, 199 cases had follow-up results, in which, 88 cases were intestinal types, 105 were diffuse types and 6 were mixed types. One hundred and nine and 54 cases were treated with Docetaxel-based and Oxaliplatin-based fi rst line chemotherapy, respectively. Other 36 cases accepted other regimens. The median evaluated cycles were 4 cycles and the effi ciency were evaluated. Results The overall response rate (ORR) of Docetaxel-based chemotherapy in intestinal-type group was 26.7%, the disease control rate (DCR) was 86.7%, the median progression-free survival (mPFS) was 4.50 months, and median overall survival (mOS) was 15.67 months. The ORR of Oxaliplatin-based chemotherapy was 15.0%, the DCR was 85.0%, the mPFS was 6.33 months, and the mOS was 21.50 months. The ORR of Docetaxel-based chemotherapy in diffuse-type group was 18.9%, the DCR was 67.9%, the mPFS was 2.53 months, and the mOS was 7.23 months. The ORR of Oxaliplatin-based chemotherapy was 10.7%, the DCR was 67.9%, the mPFS was 3.57 months, and the mOS was 7.23 months. Considering the number of patients was too small, the data of mixed type was not analyzed. Conclusion Patients with diffuse-type AGC have poorer prognosis than those with intestinal-type. There is no statistically signifi cant difference of ORR, DCR, mPFS and mOS between two different chemotherapy groups of advanced gastric cancer in Lauren type(P > 0.05).